Tipranavir

Drugs of Today

Volumn 41, Issue 11, 2005, Pages 711-720

  Temesgen, Zelalem ^a   Cainelli, Francesca ^b   Vento, Sandro ^c  

^a MAYO CLINIC   (United States)

^b University of Verona ^*

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ATAZANAVIR; DELAVIRDINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ERGOT DERIVATIVE; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STORAGE; DRUG STRUCTURE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; LIVER DYSFUNCTION; MONOTHERAPY; NAUSEA; RASH; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VOMITING;

CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; PYRIDINES; PYRONES; RITONAVIR; TREATMENT OUTCOME;

EID: 30444449824     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.11.937960     Document Type: Review

References (39)

1. Palella, F.J. Jr., Delaney, K.M., Moorman, A.C. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338: 853-60.
2. Hogg, R.S., O'Shaughnessy, M.V., Gataric, N. et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997, 349: 1294.
3. Mouton, Y., Alfandari, S., Valette, M. et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11: F101-5.
4. Thaisrivongs, S., Strohbach, J.W. Structure-based discovery of tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 1999, 51: 51-8.
5. Larder, B.A., Hertogs, K., Bloor, S. et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000, 14: 1943-8.
6. Schake, D. How flexible is tipranavir in complex with the HIV-1 protease active site? AIDS 2004, 18: 579-80.
7. Muzammil., S., Kang, L.W., Armstrong, A.A. et al. Binding energetics analysis shows a unique response of tipranavir to HIV-1 protease mutations associated with drug resistance. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005, Abst. WePp0103.
8. McCallister, S., Valdez, H., Curry, K. et al. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infectedpatients. J Acquir Immune Defic Syndr 2004, 35: 376-82.
9. Nwando, O., Themba, B. An open-label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (ritonavir) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005, Abst. TuPe7.8C01.
10. MacGregor, T.R., Sabo, J.P., Norris, S.H., Johnson, P., Galitz, L., McCallister, S. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 2004, 5: 371-82.
11. Baldwin, J.R., Boron, M.T., Wang, Y., Schneck, D.W., Hopkins, N.K. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998, Abst. 649.
12. Aptivus package insert. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT, USA, 2005.
13. Cooper, C., van Heeswijk, R., Bilodeau, M. et al. The pharmacokinetics (PK) of single-dose and steady-state tipranavir/ritonavir (TPV/r) 500 mg/200 mg in subjects with mild or moderate hepatic impairment. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005, Abst. TuPe3.1B07.
14. Washington, C.B., Duran, G.E., Man, M.C. et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19: 203-9.
15. Poppe, S.M., Slade, D.E., Chong, K.T. et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997, 41: 1058-63.
16. Rusconi, S., La Seta Catamancio, S., Citterio, P. et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000, 44: 1328-32.
17. Turner, S.R., Strohbach, J.W., Tomassi, R.A. et al. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998, 41: 3467-76.
18. Wang, Y., Daenzer, C., Wood, R. et al. The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a phase II study in antiretroviral-naive HIV-1-infected patients. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco 2000, Abst. 673.
19. Squires, K., McCallister, S., Lazzarin, A. et al. Tipranavir/ritonavir (TPV/r) demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: Correlation of baseline genotype and antiviral activity in BI 1182.52. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris 2003, Abst. 812.
20. Neubacher, D., Markowitz, M., Slater, L., Curry, R., Kohlbrenner, V., McCallister, S. Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2). 9th European AIDS Conference, Warsaw 2003, Abst. 7.2/3.
21. Gathe, J., Kohlbrenner, V.M., Pierone, G. et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. 10th Conference on Retroviruses and Opportunistic Infections, Chicago 2003, Abst. 179.
22. Tipranavir capsules, NDA 21-814. Applicant: Boehringer Ingelheim Pharmaceuticals, Inc. Anti-viral Drugs Advisory Committee (AVDAC) Briefing Document, April 19, 2005, 1-193. Available at: http://www.fda.gov/ohrms/dockets/ ac/05/briefing/2005-4139b1-02-boehringer.pdf.
23. Lazzarin, A., Mukwaya, G., Clumeck, N. et al. Tipranavir/ritonavir (TPV/r) demonstrates superior treatment response to lopinavir/r (LPV/r), amprenavir/r (APV/r) or saquinavir/r (SQV/r) in PI-experienced patients from the TPV RESIST-1 and RESIST-2 trials. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005, Abst. WePe6.3C07.
24. Grinsztejn, B., Hicks, C., Cahn, P. et al. Tipranavir/ritonavir (TPV/r) demonstrates superior immunologic response to comparator protease inhibitors (CPIs) in a PI-experienced population with advanced disease. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005, Abst. WePe16.7B07.
25. Schapiro, J., Cahn, P., Trottier, B. et al. Effect of baseline genotype on response to tipranavir/ritonavir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: The phase 3 RESIST-1 and -2 trials. 12th Conference on Retroviruses and Opportunistic Infections, Boston 2005, Abst. 104.
26. Cooper, D., Hicks, C., Cahn, P. et al. 24-Week RESIST study analyses: The efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen. 12th Conference on Retroviruses and Opportunistic Infections, Boston 2005, Abst. 560.
27. Valdez, H., McCallister, S., Kohlbrenner, V., Mayers, D. Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400 copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced HIV+patients. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005, Abst. WeOa0205.
28. Pierone, G., Drulak, M., Arasteh, K. et al. A long-term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir (TPV/r) use in HIV-1-infected patients. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005, Abst. WePe6.2C05.
29. Walmsley, S., Leith, J., Katlama, C. et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): Interim analysis of BI1182.51. The XV International AIDS Conference, Bangkok 2004, Abst. WeOrB1236.
30. Roszko, P.J., Curry, K., Brazina, B. et al. Standard doses of efavirenz (EFV), zidovudine (ZDV), tenofovir (TDF), and didanosine (ddl) may be given with tipranavir/ritonavir (TPV/r). 3rd IAS Conference on HIV Pathogenesis and Treatment, Paris 2003, Abst. 812.
31. Philips, L., Borin, M.T., Hopkins, N.K., Daenzer, C.L., Wang, Y. The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco 2000, Abst. 81.
32. Sabo, J.P., MacGregor, T.R., Lamson, M. et al. Pharmacokinetics of tipranavir and nevirapine. A pharmacokinetic study in healthy volunteers. HIV DART 2000: Frontiers in drug development for antiretroviral therapies, San Juan 2000, Abst. 103.
33. Van Heeswijk, R., Sabo, J.P., MacGregor, T. et al. The effect of tipranavir/ritonavir 500 mg/200 mg b.i.d. (TPV/r) on the pharmacokinetics of fluconazole in healthy volunteers. 5th International Workshop on Clinical Pharmacology in HIV Therapy, Rome 2004, Abst. 20.
34. Van Heeswijk, R., Sabo, J.P., MacGregor, T. et al. The pharmacokinetic interaction between single-dose rifabutin and steady state tipranavir/ritonavir 500 mg/200 mg (TPV/r) in healthy volunteers. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C. 2004, Abst. A-456.
35. Doyon, L., Tremblay, C., Wardrop, E. et al. Characterization of HIV-1 isolates showing decreased susceptibility to tipranavir and their inhibition by tipranavir containing drug mixtures. XII International HIV Drug Resistance Workshop, Los Cabos 2003, Abst. 12.
36. Doyon, L., Tremblay, C., Cartier, M., Cordingley, M. In vitro susceptibility of HIV-1 to tipranavir. Antivir Ther 2002, 7 (Suppl. 1): S12.
37. Hall, D., McCallister, S., Neubacher, D., Kraft, M., Mayers, D.L. Characterisation of treatment-emergent resistance mutations in two phase II studies of tipranavir (TPV). XII International HIV Drug Resistance Workshop, Los Cabos 2003, Abst. 13.
38. Cooper, D., Hall, D., Jayaweera, D. et al. Baseline phenotypic susceptibility to tipranavir/ritonavir (TPV/r) is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52). 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003, Abst. 596.
39. Schwartz, R., Kazanjan, P., Slater, L.N. et al. Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/ritonavir) in multiple PI-failure patients (BI 1182.2). 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002, Abst. 562 T.